Use of Vivitrol for Alcohol and Opioid Addiction



Similar documents
The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction

How To Treat Anorexic Addiction With Medication Assisted Treatment

John Viernes, Jr. Executive Director. Substance Abuse Prevention and Control (SAPC) Los Angeles County Department of Public Health

Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction

VIVITROL (EXTENDED-RELEASE INJECTABLE NALTREXONE) MEDICAL PROTOCOL AND PROCEDURES

In 2010, approximately 8 million Americans 18 years and older were dependent on alcohol.

Alkermes, Inc. 852 Winter Street Waltham, MA

Beyond SBIRT: Integrating Addiction Medicine into Primary Care

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings

Financial Disclosures

Heroin Overdose Trends and Treatment Options. Neil A. Capretto, D.O., F.A.S.A.M. Medical Director

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Prior Authorization Guideline

Substitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015

Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )

Medication-Assisted Addiction Treatment

EPIDEMIC 4.6 % OF INDIVIDUALS USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH.

A G U I D E F O R U S E R S N a l t r e x o n e U

Medication is not a part of treatment.

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act

Opioid Treatment Services, Office-Based Opioid Treatment

Frequently asked questions

CLINICAL POLICY Department: Medical Management Document Name: Vivitrol Reference Number: NH.PHAR.96 Effective Date: 03/12

Naltrexone and Alcoholism Treatment Test

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd

Substance Abuse Treatment. Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

It is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose.

Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions

Update and Review of Medication Assisted Treatments

Buprenorphine Therapy in Addiction Treatment

Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

Medication Assisted Treatment

ARCHIVED BULLETIN. Product No L SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E

Medications Used in the Treatment of Addiction Developed by Randall Webber, MPH. Alcohol Withdrawal

Opioid overdose can occur when a patient misunderstands the directions

Treatment of opioid use disorders

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

Information for Pharmacists

5317 Cherry Lawn Rd, Huntington, WV Phone: (304) Fax: (304) Welcome

Advanced Treatment for Opioid & Alcohol Dependence. John Larson, M.D. Corporate Medical Director Gateway Foundation

MEDICAID DRUG SPENDING ON ANTI- ADDICTION MEDICATION AND OPIOID ADDICTION REFRESHER

OVERVIEW OF MEDICATION ASSISTED TREATMENT

Heroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?

Medication-Assisted Treatment for Opioid Addiction

Using Drugs to Treat Drug Addiction How it works and why it makes sense

Heroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?

Office-based Treatment of Opioid Dependence with Buprenorphine

Update on Buprenorphine: Induction and Ongoing Care

UCLA-SAPC Lecture Series March 13, Gary Tsai, M.D. Medical Director Substance Abuse Prevention and Control

Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio

Allyse Adams PC, LICDC Oriana House, Inc.

Use of Pharmacotherapies by Substance Abuse Treatment Facilities

Heroin. How is Heroin Abused? What Other Adverse Effects Does Heroin Have on Health? How Does Heroin Affect the Brain?

A prisoners guide to buprenorphine

John R. Kasich, Governor Orman Hall, Director

The ABCs of Medication Assisted Treatment

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment

BUPRENORPHINE TREATMENT

Section Editor Andrew J Saxon, MD

Use of Buprenorphine in the Treatment of Opioid Addiction

HEROIN AND RELATED OPIATES

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

Brain Damage & Recovery: The Resilience of the Brain, Addiction Impact & Therapeutic Repair. Michael Fishman, MD Director of Young Adult Program

Testimony on Addressing Heroin and Opioid Addiction. Theodore Dallas. Secretary, Department of Human Services. Center for Rural Pennsylvania

Best Practices in Opioid Dependence Treatment

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

BUPRENORPHINE TREATMENT

Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective

Medication Assisted Treatment of Substance Use Disorders

Reintegration. Recovery. Medication-Assisted Treatment for Alcohol Dependence. Reintegration. Resilience

Naltrexone: (Vivitrol )

Treatment of Opioid Addiction. Miriam Komaromy, MD Associate Director, Project ECHO University of New Mexico Health Sciences Center

One example: Chapman and Huygens, 1988, British Journal of Addiction

Opioid/Opiate Dependent Pregnant Women

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

Jane Maxwell, UT Addiction Research Institute, Prescription Pain Medications and Heroin: A Changing Picture

8/1/2014. Who We Are. BHG s Medical Mission. BHG Company Overview

Naltrexone for Opioid & Alcohol Use Disorders

Using Buprenorphine in an Opioid Treatment Program

EPIDEMIOLOGY OF OPIATE USE

What is Addiction and How Do We Treat It? Roger D. Weiss, M.D. Professor of Psychiatry, Harvard Medical School Clinical Director, Alcohol and Drug

Tufts Health Care Institute Program on Opioid Risk Management Pharmacotherapy for Prescription Opioid Addiction: Implications for Pain Management

Like cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.

MEDICAL ASSISTANCE BULLETIN

Transcription:

Use of Vivitrol for Alcohol and Opioid Addiction Ken Bachrach, Ph.D. Clinical Director, Tarzana Treatment Centers, Inc. kbachrach@tarzanatc.org

What is Vivitrol? An injectable from of naltrexone, which as a pill was FDA approved in 1984 Reduces cravings or the urge to drink alcohol Blocks the effects of opiates and also reduces cravings to use opiates Compliance not a major issue, since it lasts 30 days

Extended-Release Injectable Naltrexone (Vivitrol) FDA approval for alcohol 2006 FDA approval for opiates - 2010 380 mg intramuscular injection once every 30 days Must be refrigerated Needs to be at room temperature at time of injection Opioid antagonist should be opioid free for at least 7 days

Extended-Release Injectable Naltrexone (Vivitrol) Vivitrol represents an improvement in the technology delivery system, which was developed by Alkermes Naltrexone is infused into polymers, which are widely used in medicine (e.g., absorbable sutures) These polymer microspheres slowly release the naltrexone over 30 days It is administered via a gluteal IM injection, alternating buttocks each injection Must not be administered intravenously or subcutaneously

Opiates Bind to the Mu Receptor in Agonist the Brain Binds to the receptor and produces strong euphoric effects (e.g., heroin) Partial Agonist Binds to the receptor with weaker euphoric effects (e.g., buprenorphine) Antagonists Binds to the receptor with no opioid effects (e.g., naloxone)

Partial vs. Full Opiate Mu Agonist death Opiate Effect Full Agonist (e.g., methadone) ceiling effect Partial Agonist (e.g., buprenorphine) Dose of Opiate Antagonist ( Vivitrol)

Vivitrol Carton Supplies

Common Concerns about Vivitrol Vivitrol IS NOT ADDICTIVE There is no pleasure or euphoria from taking Vivitrol One cannot become dependent on Vivitrol There is no withdrawal when one stops taking Vivitrol Vivitrol does not block a person s ability to experience pleasure through everyday activities

Side effects The most common side effects are: Injection site reaction 69% Nausea 33% Headache 22% Fatigue 20% Side effects usually peak by day 3 after the injection and then subside Side effects usually decline with each subsequent injection The number of people who stop taking Vivitrol due to side effects is very small

Who should take Vivitrol? A person who is dependent on alcohol or opiates; and Who reports significant cravings to use alcohol or opiates as measured by a score of 10 or above on the Urge to Drink Scale

URGE TO DRINK SCALE 5 items INSTRUCTIONS: The following questions are designed to help you assess an important aspect of your recovery status: the urge to drink. Complete this form by thinking about the past week and placing a check mark next to the response that is most true for you. 1. How often have you thought about drinking or about how good a drink would make you feel during this period? Never, that is, 0 times during this period of time.(0) Rarely, that is, 1 to 2 times during this period of time.(1) Occasionally, that is, 3 to 4 times during this period of time.(2) Sometimes, that is, 5 to 10 times during this period or 1 to 2 times a day.(3) Often, that is, 11 to 20 times during this period or 2 to 3 times a day.(4) Most of the time, that is, 20 to 40 times during this period or 3 to 6 times a day.(5) Nearly all of the time, that is, more than 40 times during this period or more than 6 times a day.(6) SCORES OF 10 OR HIGHER ASSOCIATED WITH INCREASED RISK FOR RELAPSE.

Urge to Drink Scale Items 2-5 2. At its most severe point, how strong was your urge to drink? 3. How much time have you spent thinking about drinking or about how good a drink would make you feel during this period? 4. How difficult would it have been to resist taking a drink during this period of time if you had know a bottle was in your house? 5. Keeping in mind your responses to the previous questions, please rate your overall average alcohol urge to drink for the state period of time.

Reasons to Use Vivitrol Significantly reduces cravings to use alcohol for most patients Decreases the likelihood of relapse Allows the patient to focus more on their recovery rather than just managing cravings Gives patients more choices and new options

Continuation / Discontinuation There is not an established time frame for how long one should stay on Vivitrol Since we know that relapse is most likely during the first 90 days in treatment, patients should stay on Vivitrol at least three months, if they are benefitting from the medication Some individuals may benefit from being on Vivitrol for up to one year or longer, especially if they have strong cravings to use and a long history of addiction

Cost of Vivitrol Expensive Medication Cost can be $500-$550 (through 340B) and up for a 30 day dose retail price $1000-1200 Must be obtained from specialty pharmacies Addition costs to pay medical provider for injection Insurance companies are now starting to cover Vivitrol since they are realizing that it may actually save them money for subsequent treatment costs Medicaid is paying in California for Vivitrol

TTC s Experience with Vivitrol First injection given 9-11-2008 Have had over 1000 patients on Vivitrol We are one of the leading prescribers of Vivitrol nationally In 2013 we administered 676 Vivitrol injections to 330 patients

UCLA Evaluation Findings of LA Country Pilot Project Treatment adherence (at least 2 doses) was almost 70%, similar to what was found with other studies and higher than noted with oral naltrexone Engagement in treatment (LOS at least 30 days) is higher for patients who took at least one dose of Vivitrol compared to other patients admitted for primary alcohol use

UCLA Evaluation Findings of LA Country Pilot Project Patients reported significant decrease in alcohol use reducing their prior month s use from 17 days to less than 2 days Over the course of 8 weeks, cravings for alcohol were reduced from an average score of 15.7 on the Urge to Drink scale to 7.3 Less than 10% of patients reported any side effects or few left treatment because of the side effects

Patient Interview